Hi Irene. I'm not sure if this is the one that Tammy Faye talked about, but there is an orally administered angiogenesis inhibitor being used in Phase III clinical trials, that is made by Schering. It is known as PTK787/ZK 222584.
PTK787/ZK 222584 is a novel oral angiogenesis inhibitor that potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.
I believe that this drug is very similar in action to Genentech's experimental drug lapatinib, that we all think is so promising, particularly for the treatment of refractory HER2/neu breast cancer. This is HER2/neu that has progressed after Herceptin therapy.
Tom
|